Literature DB >> 9926233

Immune escape mechanisms in Hodgkin's disease.

S Poppema1, M Potters, L Visser, A M van den Berg.   

Abstract

BACKGROUND: The nodular sclerosis and mixed cellularity subtypes of Hodgkin's disease are histologically characterised by a small population of neoplastic cells, the so-called Reed-Sternberg cells and their mononuclear variants (RS cells) and an extensive admixture of other cell types including lymphocytes, plasma cells, eosinophils, and histiocytes. The nature of this infiltrate is largely known, but the mechanisms and functional effects are not. The small lymphocytes immediately surrounding the RS cells are mostly CD4+ T cells that express early activation markers. The absence of prominent specific cytotoxic T cell or natural killer (NK) cell populations seems to argue against a Th1-type response, whereas the sometimes prominent admixture of plasma cells and eosinophils is suggestive of a Th2-type response. Enrichment of the CD4 T-cell population may result from selective influx of CD4 T cells or from selective depletion of CD8 and NK cells. RESULTS AND DISCUSSION: The T cells surrounding RS cells have an immuno-phenotype and cytokine production capability consistent with a Th2-type response. RS cells express several members of the TNF receptor family such as the FAS ligand (CD95L) that may induce apoptosis of activated, FAS expressing, CD8+ T cells and NK cells. The RS cells also produce TGF beta and interleukin-10 that may downmodulate the Th1 response. In addition, the Reed-Sternberg cells produce the chemokine TARC that could lead to the specific attraction of a Th2 T-cell subset.
CONCLUSION: RS cells have several mechanisms that may allow it to escape an effective immune response. The relative contributions of each of these and other potential mechanisms are not yet known.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9926233     DOI: 10.1093/annonc/9.suppl_5.s21

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  31 in total

Review 1.  Adoptive immunotherapy for Hodgkin's lymphoma.

Authors:  Alana A Kennedy-Nasser; Catherine M Bollard; Cliona M Rooney
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

Review 2.  Immunotherapies for Hodgkin's lymphoma.

Authors:  Yvette L Kasamon; Richard F Ambinder
Journal:  Crit Rev Oncol Hematol       Date:  2007-11-19       Impact factor: 6.312

3.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

Authors:  Gianpietro Dotti; Barbara Savoldo; Martin Pule; Karin C Straathof; Ettore Biagi; Eric Yvon; Stephane Vigouroux; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

4.  Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010.

Authors:  Satish Gopal; Kelly E Martin; Kristy L Richards; Joseph J Eron
Journal:  AIDS Res Hum Retroviruses       Date:  2011-12-01       Impact factor: 2.205

5.  A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Achim Rothe; Stephanie Sasse; Max S Topp; Dennis A Eichenauer; Horst Hummel; Katrin S Reiners; Markus Dietlein; Georg Kuhnert; Joerg Kessler; Carolin Buerkle; Miroslav Ravic; Stefan Knackmuss; Jens-Peter Marschner; Elke Pogge von Strandmann; Peter Borchmann; Andreas Engert
Journal:  Blood       Date:  2015-04-17       Impact factor: 22.113

6.  Non-AIDS-Defining Malignancies in the HIV-Infected Population.

Authors:  Chia-Ching J Wang; Michael J Silverberg; Donald I Abrams
Journal:  Curr Infect Dis Rep       Date:  2014-06       Impact factor: 3.725

7.  Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS.

Authors:  Robert J Biggar; Elaine S Jaffe; James J Goedert; Anil Chaturvedi; Ruth Pfeiffer; Eric A Engels
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

8.  CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse.

Authors:  F R Abdul Razak; A Diepstra; L Visser; A van den Berg
Journal:  Genes Immun       Date:  2016-07-28       Impact factor: 2.676

9.  The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.

Authors:  Evgeny Klyuchnikov; Ulrike Bacher; Nicolaus Kröger; Ilya Kazantsev; Tatjana Zabelina; Francis Ayuk; Axel Rolf Zander
Journal:  Adv Hematol       Date:  2010-10-26

10.  Diagnostic impact of molecular lineage analysis on paraffin-embedded tissue in hematolymphoid neoplasia reclassified by current WHO criteria.

Authors:  Leonard Hwan Cheong Tan; Lily-Lily Chiu; Evelyn Siew Chuan Koay
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.